Skip to main content

IL-23

    Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting. COSMOS: Guselkumab in TNF-IR PsA. # OP0230m Coates LC, et al. C-…
    New GRAPPA 2021 PsO and PsA Treatment Recommendations by Dr. Rachel Tate ( @uptotate)

    The evidence-based recommendation
    2 years 10 months ago
    New GRAPPA 2021 PsO and PsA Treatment Recommendations by Dr. Rachel Tate ( @uptotate) The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021. Read more... https://t.co/AnHQGA8aKs https://t.co/4c18j4h54T
    Video: Personalization of PsA Treatment: Dr. Robert Chao ( @doctorRBC)

    Dr. Robert Chao reviews a talk given by Dr. Lau
    2 years 10 months ago
    Video: Personalization of PsA Treatment: Dr. Robert Chao ( @doctorRBC) Dr. Robert Chao reviews a talk given by Dr. Laura Coates entitled, "Towards personalized treatment strategies for psoriatic arthritis", presented #EULAR2021. https://t.co/LeocvUyZ7N https://t.co/g6ApPL0Pui
    It seems like every conference we are presented with data on the newest biologic for treatment of psoriatic arthritis, but the question is, do we need it? Oral presentation (6937) discussed that…
    RT @Yuz6Yusof: No clear winner here. The majority would use #IL23 inhibitors as either 2nd or 3rd line bDMARDs and for #
    2 years 10 months ago
    No clear winner here. The majority would use #IL23 inhibitors as either 2nd or 3rd line bDMARDs and for #psoriaticarthritis with severe #psoriasis. Thank you for participating in the polls #EULAR2021 @RheumNow https://t.co/b8wzaRVTqw
    EULAR 2021 - Day 2 Podcasts

    Check out this compilation of our EULAR 2021 Day 2 broadcasts below.

    You can also follow t
    2 years 10 months ago
    EULAR 2021 - Day 2 Podcasts Check out this compilation of our EULAR 2021 Day 2 broadcasts below. You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud. https://t.co/GskToSkfLk https://t.co/nF2FkHgBtu
    RT @uptoTate: Poster #POS1031 pooled VOYAGE 1&2 and DISCOVER 1&2, GI-related SAE rates low. No uveitis, opportun
    2 years 10 months ago
    Poster #POS1031 pooled VOYAGE 1&2 and DISCOVER 1&2, GI-related SAE rates low. No uveitis, opportunistic infections, or new onset/exacerbation of IBD in GUS-treated pts. No new safety concerns were identified through 1-year follow up. #EULAR2021 @RheumNow https://t.co/7NxeOu6FLW